Brief: Wilex signs antibody license agreement with Telix Pharmaceuticals Limited

Heidelberg Pharma AG

16/01/2017 08:05

Jan 16 (Reuters) - Wilex AG  WL6G.DE : 
    * Wilex signs antibody license agreement with Telix Pharmaceuticals Limited 
    * Wilex has granted Telix worldwide licensing rights to further develop and commercialize 
REDECTANE molecular imaging program 
    * Under agreement, Telix will, as a first step, invest in an improved manufacturing process 
for antibody 
    * Under terms of agreement, Wilex is eligible to receive up-front and milestone payments 
totaling $3.7 million 
    * In addition, Wilex is eligible to receive significant royalties on global net sales of 
REDECTANE, commensurate with a Phase III asset 
 
Source text for Eikon:  ID:nEQ9639jf  
Further company coverage:  WL6G.DE  
 
 (Gdynia Newsroom) 
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))